Affymetrix® Launches Next-Generation microRNA Solution
28 February 2011 - 7:00PM
Business Wire
Affymetrix, Inc. (NASDAQ:AFFX) today launched the GeneChip®
miRNA 2.0 Array. This enhanced version of its best-in-class
microRNA (miRNA) interrogation solution will support the research
community’s pursuit of personalized medicine by accelerating the
identification of biomarkers and gene expression signatures
associated with disease. Built on the success of the
first-generation miRNA Array design, turnkey assay, and data
analysis solution, the GeneChip miRNA 2.0 Array combines the most
comprehensive miRNA view with the highest level of sensitivity
available.
This new GeneChip miRNA 2.0 Array offers the broadest coverage
of known miRNA, encompassing 131 organisms on a single array, and
nearly doubles the content of the previous array by updating the
mature miRNA, small cajal body-specific RNA (scaRNA), and small
nucleolar RNA (snoRNA). Moreover, it is the only array that
contains unique probe sequences designed to independently
interrogate human, mouse, and rat precursor RNA (pre-miRNA) and
mature miRNA in the same experiment, which increases researchers’
ability to get closer to biology by measuring changes in these key
regulatory molecules.
“I’ve had great success using the first-generation miRNA Array
in my work profiling frozen and archival (FFPE) biopsy specimens
for predicting effectiveness of therapeutics such as
chemo-radiotherapy treatment in head and neck cancers—it’s robust,
straightforward to use, and the data quality is reliable,” remarked
Catherine Dumur, PhD, Director of the Molecular Morphology Genomics
Facility and Associate Professor at Virginia Commonwealth
University. “The release of a potentially more sensitive version
with updated content will be helpful to my current research, based
on the good performance of the first version.”
The GeneChip miRNA 2.0 Array has excellent sensitivity across
every miRNA transcript. Testing demonstrates that the array
reproducibly detects 94 percent of all transcripts present in the
sample at 1.0 attomole. Coupled with the Genisphere FlashTag™
Biotin RNA Labeling Kit, the new array maintains the same simple
and robust assay protocol, requiring only a 45-minute assay with no
amplification or purification steps, and as little as 100 nanograms
of input total RNA. The entire solution—array, assay, and
software—is compatible with current GeneChip® Systems from
Affymetrix.
“This new GeneChip miRNA 2.0 Array demonstrates Affymetrix’
commitment to stay at the forefront of gene expression analysis and
to provide life scientists like Dr. Dumur with relevant and timely
content that is critical to research in gene expression and
cellular function,” said Kevin Cannon, PhD, Vice President of
Expression Applications at Affymetrix. “With its complete and
comprehensive view of all coding and non-coding miRNA, researchers
gain greater access to the entire miRNA spectrum—from human to
model organisms, at a competitive price.”
In addition, miRNAs discovered using the GeneChip miRNA 2.0
Array can be validated using the new QuantiGene® 2.0 miRNA Assay
Kit. This kit, which will be available soon, uses reporter
amplification and generates quantitative information directly from
samples without the need for miRNA isolation, cDNA synthesis, or
PCR. Detection probes are pre-validated for specificity and
sensitivity and are designed to the same target sequences used in
the GeneChip miRNA 2.0 Array. Only on the Affymetrix RNA platform
will researchers be able to go from whole-genome analysis to
single-gene validation in a single experiment.
About Affymetrix
Affymetrix technology is used by the world's top pharmaceutical,
diagnostic, and biotechnology companies, as well as leading
academic, government, and nonprofit research institutes. More than
2,000 systems have been shipped around the world and more than
23,000 peer-reviewed papers have been published using the
technology.
Affymetrix is headquartered in Santa Clara, Calif., and has
manufacturing facilities in Santa Clara, Cleveland, Ohio, and
Singapore. The company has about 900 employees worldwide and
maintains sales and distribution operations across Europe and Asia.
For more information about Affymetrix, please visit
http://www.affymetrix.com.
Disclaimer
The information stated above was prepared by Affymetrix, Inc.
and reflects solely the opinion of Affymetrix, Inc. Nothing in this
statement shall be construed to imply any support or endorsement of
Affymetrix, Inc., or any of its products, by any other institution
mentioned, including Virginia Commonwealth University, their
officers, agents and employees.
Forward-looking statements
All statements in this press release that are not historical are
“forward-looking statements” within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix’ “expectations,” “beliefs,” “hopes,”
“intentions,” “strategies” or the like. Such statements are subject
to risks and uncertainties that could cause actual results to
differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix’ Form 10-K for the
year ended December 31, 2009, and other SEC reports for subsequent
quarterly periods.
NOTE: Affymetrix, the Affymetrix logo, QuantiGene, and GeneChip
are trademarks or registered trademarks of Affymetrix Inc.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2023 to Aug 2024